Summary
Advanced glycation is an important pathogenic mechanism in the development of diabetic complications. However, other biochemical processes, such as the polyol pathway or lipid and protein oxidation which can interact with advanced glycation can also yield tissue fluorescence and may also be implicated in the genesis of diabetic microangiopathy. Aminoguanidine is an inhibitor of advanced glycation, but it is not known if all of its effects are mediated by this mechanism. The present study explores the relative contributions of aldose reductase, oxidative stress and advanced glycation on the development of aortic and renal fluorescence and urinary albumin excretion in streptozotocin diabetic rats. The study groups included non-diabetic (control), streptozotocin diabetic rats and diabetic rats receiving aminoguanidine, the anti-oxidants butylated hydroxytoluene and probucol and the aldose reductase inhibitor, ponalrestat. Serial measurements of glycaemic control and urinary albumin excretion were performed every 8 weeks. At 32 weeks, animals were killed, tissues removed and collagen extracted for measurement of fluorescence. Diabetic rats had increased fluorescence in aorta, glomeruli and renal tubules. Aminoguanidine prevented an increase in fluorescence at all three sites suggesting that diabetes-related tissue fluorescence is predominantly due to advanced glycation. Ponalrestat retarded fluorescence in aorta only and butylated hydroxytoluene attenuated fluorescence at the renal sites but not in the aorta. Diabetic rats had increased renal cortical sorbitol levels. Ponalrestat normalized renal cortical sorbitol levels but aminoguanidine did not affect this parameter. The only agent to decrease plasma thiobarbituric acid reactive substances was butylated hydroxytoluene. Diabetic rats developed albuminuria over the 32-week period. This increase in urinary albumin excretion was only attenuated significantly by aminoguanidine therapy, but not by probucol or ponalrestat. The effects of butylated hydroxytoluene on albuminuria were intermediate between aminoguanidine-treated and untreated diabetic rats. The failure of either antioxidants or aldose reductase inhibition to reproduce the renal effects of aminoguanidine suggest that aminoguanidine may act predominantly via inhibition of advanced glycation and not via the alternative biochemical processes evaluated in this study.
Article PDF
Similar content being viewed by others
Abbreviations
- AGE:
-
Advanced glycated end products
- AG:
-
aminoguanidine
- TBARS:
-
Thiobarbituric acid reactive substances
- BHT:
-
butylated hydroxytoluene
References
Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H (1993) Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90: 6434–6438
Odetti PR, Borgoglio A, De Pascale A, Rolandi R, Adezati L (1990) Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 39: 796–801
Suarez G, Rajaram R, Kailash CB, Ororisky AL, Goidl JA (1988) Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats. J Clin Invest 82: 624–627
Ahmed N, Furth AJ (1992) Failure of common glycation assays to detect glycation by fructose. Clin Chem 38(7): 1301–1303
Baynes JW (1991) Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405–412
Chisolm GM, Irwin KC, Penn MS (1992) Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41 [Suppl 2]: 61–66
Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328–1334
Tada H, Oida K, Kutsumi Y, Shimada Y, Nakai T, Miyabo S (1992) Effects of probucol on impaired cardiac performance and lipid metabolism in streptozocin-induced diabetic rats. J Cardiovasc Pharmacol 20: 179–186
Srivastava SK, Ansari NH (1988) Prevention of sugar-induced caractogenesis in rats by butylated hydroxytoluene. Diabetes 37: 1505–1508
Cameron NE, Cotter MA, Maxfield EK (1993) Anti-oxidant treatment prevents the development of peripheral nerve dysfunction in streptozotocin-diabetic rats. Diabetologia 36: 299–304
Daniels BS, Hostetter TH (1989) Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes 38: 981–986
Schmidht FH (1961) Enzymatic determination of glucose and fructose simultaneously. Klin Wochenschr 39: 1244–1247
Cooper ME, Allen TJ, Macmillan P et al. (1991) Effect of genetic hypertension on diabetic nephropathy in the ratfunctional and structural characteristics. J Hypertens 6: 1009–1016
Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254
Sener A, Malaisse WJ (1990) A sensitive radioisotopic method for the measurement of NAD(P)H: its application to the assay of metabolites and enzymatic activities. Anal Biochem 186: 236–242
Wills ED (1969) Lipid peroxide formation in microsomes. Biochem J 113: 315–324
Cooper ME, Vranes DA, Panagiotopoulos S, Allen GJ, Goodall I, Jerums G (1990) Hyperlipidaemia increases albuminuria in hypertensive and normotensive rats. Clin Exp Pharmacol Physiol 17: 225–228
Soulis T, Cooper ME, Layton G, Allen T, Jerums G (1988) Aminoguanidine reduces tissue fluorescence but not albuminuria in diabetic rats: In: Ryal RG (ed) Proceedings. Glycated proteins in diabetes mellitus. Univ of Adelaide, Adelaide, Australia, p 310–320
Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A (1986) Aminoguanidine prevents diabetes-induced arterial protein cross-linking. Science 232: 1629–1632
Monnier VM, Kohn RR, Cerami A (1984) Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci 81: 583–587
Beisswenger PJ, Moore LL, Curphey TJ (1993) Relationship between glycemic control and collagen-linked advanced glycation and products in type I diabetes. Diabetes Care 16(5): 689–694
Edelstein D, Brownlee M (1992) Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 35(1): 96–97
Itakura M, Yoshikawa H, Bannai C et al. (1991) Aminoguanidine decreases urinary albumin and high-molecular weight proteins in diabetic rats. Life Sci 49: 889–897
Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R (1992) Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA 89: 12043–12047
Makita Z, Vlassara H, Rayfield et al. (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science 258(5082): 651–653
Cameron NE, Cotter MA, Dines K, Love A (1992) Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 35: 946–950
Kumari K, Umar S, Bansal V, Sahib MK (1991) Monoaminoguanidine inhibits aldose reductase. Biochem Pharmacol 4: 1527–1528
Kumari K, Umar S, Bansal B, Sahib MK (1991) Inhibition of diabetes-associated complications by nucleophilic compounds. Diabetes 40: 1079–1084
Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nicklander KK, Low PA (1991) Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 88: 6107–6111
Chang WP, Dimitriadis E, Allen T, Dunlop ME, Cooper M, Larkins RG (1991) The effect of aldose reductase inhibitors on glomerular prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia 34: 225–231
Beyer-Mears A, Murray FT, Cruz E, Rountree J, Sciadini M (1992) Comparison of sorbinil and ponalrestat (Statil) diminution of proteinuria in the BB rat. Pharm 45: 285–291
Cohen MP, Klepser H, Wu VL (1991) Evaluation of the effect of aldose reductase inhibition on increased basement collagen fluorescence in diabetic rats. Gen Pharmacol 22: 603–606
Maurel E, Shuttleworth CA, Bouissou H (1987) Interstitial collagens and ageing in human aorta. Virchows Arch A (Pathol Anat Histopathol) 410: 383–390
Martinez-Hernandez A, Amenta PS (1983) The basement membrane in pathology. Lab Invest 48: 656–677
Richard S, Tamas C, Sell DR, Monnier VM (1991) Tissuespecific effects of aldose reductase inhibition on fluorescence and cross-linking of extracellular matrix in chronic galactosemia. Diabetes 40: 1049–1056
Ghahary A, Chakrabarti S, Sima AAF, Murphy LJ (1991) Effect of insulin and statil on aldose reductase expression in diabetic rats. Diabetes 40: 1391–1396
Reddy VN, Lin LR, Giblin FJ, Lou M, Kador PF, Kinoshita JH (1992) The efficacy of aldose reductase inhibitors on polyol accumulation in human lens and retinal pigment epithelium in tissue culture. J Ocul Pharmacol 8: 43–52
Carmeron NE, Leonard MB, Ross IS, Whiting PH (1986) The effects of sorbinil on peripheral nerve conduction velocity, polyol concentrations and morphology in the streptozotocin-diabetic rat. Diabetologia 29: 168–174
Lyons TJ (1993) Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 71: 26 B-31 B
Kristal BS, Yu BP (1992) An emerging hypothesis: synergistic induction of aging by free radicals and Maillard reactions. J Gerontol 47(4): B107-B114
Hodge JE (1953) Dehydrated foods: chemistry of browning reactions in model systems. Agric Food Chem 1: 928–943
Hayashi T, Namiki M (1986) Role of sugar fragmentation in the Maillard reactions. In: Fujimaki M, Namiki M, Kato H (eds) Amino-carbonyl reactions in food and biological systems. Elsevier, Amsterdam, pp 29–38
Hunt JV, Wolff SP (1991) Oxidative glycation and free radical production: a causal mechanism of diabetic complications. Free Rad Res Comms 12–13: 115–123
McCance DR, Dyer DG, Dunn JA et al. (1993) Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 91: 2470–2478
Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW (1994) Glycation, glyoxidation and crosslinking of collagen by glucose. Diabetes 43: 676–683
Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41: 1286–1292
Odetti P, Fogarty J, Sell DR, Monnier VM (1992) Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 42: 153–159
Hicks M, Delbridge L, Yue DK, Reeve TS (1988) Catalysis of lipid peroxidation by glucose and glycosylated collagen. Biochem Biophys Res Commun 151: 649–655
Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D (1986) Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest 77: 641–644
Carew TE, Schwenke DC, Steinberg D (1987) Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of athersclerosis in the watanabe heritable hyperlipidemic rabbit. Proc Natl Acad USA Sci 84: 7725–7729
Mamo JC, Elsegood CL, Umeda Y, Hirano T, Redgrave TG (1993) Effect of probucol on plasma clearance and uptake of chylomicrons and VLDLs in normal and diabetic rats. Arterioscler Thromb 13: 231–239
Parinandi NI, Thompson EW, Schmid HH (1990) Diabetic heart and kidney exhibit increased resistance to lipid peroxidation. Biochim Biophys Acta 1047: 63–69
Oster MH, Llobet JM, Domingo JL, German JB, Keen CL (1993) Vanadium treatment of diabetic sprague dawley rats results in tissue vanadium accumulation and pro-oxidant effects. Toxicology 83: 115–130
Yoshino G, Matsushita M, Maeda et al. (1992) Effect of probucol on recovery from streptozotocin diabetes in rats. Horm Metab Res 24: 306–309
Tilton RG, Chang K, Hasan KS et al. (1993) Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42: 221–232
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Soulis-Liparota, T., Cooper, M.E., Dunlop, M. et al. The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia 38, 387–394 (1995). https://doi.org/10.1007/BF00410275
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00410275